Graphite Bio Inc logo

Graphite Bio Inc Funding & Investors

Graphite Bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. The company’s platform harnesses the natural cellular process of homology directed repair (HDR) and targeted DNA integration to precisely repair genetic defects at their source. Graphite Bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives

graphitebio.com

Total Amount Raised: $195,749,984

Graphite Bio Inc Funding Rounds

  • Series A

    $45,000,000

    Series A Investors

    Samsara BioCapital
    Versant Ventures
  • Series B

    $150,749,985

    Series B Investors

    Ra Capital Management
    Rock Springs Capital
    Logos Capital
    Henderson Global Investors
    Venrock Healthcare Capital Partners
    Fidelity Investments
    Deerfield Management
    Cormorant Asset Management
    OrbiMed
    Surveyor Capital
    Versant Ventures
    Samsara BioCapital
    Federated Kaufmann Fund
    Perceptive Advisors
Funding info provided by Diffbot.